Dear editor
I read "Dexamethasone intravitreal implant in the treatment of diabetic macular edema" published July 2015 by Dugel et al. 1 This article is very interesting in terms of providing an outline of the role of inflammation in the pathogenesis of diabetic macular edema and explaining the value of corticosteroids in the treatment of diabetic macular edema.
However, I would like to draw your attention to the data presented for ILUVIEN ® (fluocinolone acetonide; FAc) in Table 2 , which has been presented incorrectly and does not reflect the approved product and dose in Europe. ILUVIEN is indicated in Europe for the treatment of vision impairment associated with chronic diabetic macular edema, considered insufficiently responsive to available therapies 2 and is approved in Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden, and the United Kingdom. ILUVIEN was launched in the United Kingdom in April 2013, Germany in May 2013, and Portugal in January 2015. presented the data for the 0.5 µg of FAc per day, which was studied in the FAME studies but is not the approved dose in Europe. This needs to be explained to the reader as the data that are relevant to the currently marketed product are those of the 0. We would like to thank Dr Hall for his interest in our recently published review article, 1 and Clinical Ophthalmology for inviting us to respond to the points raised in his letter.
It should be noted that the primary aim of our article was to review the clinical efficacy and safety of dexamethasone intravitreal implant in the treatment of diabetic macular edema; for this reason only brief mention was made of other intravitreal corticosteroid delivery systems. Comparative data were limited to a short summary (Table 2 ) of the properties of Ozurdex ® (dexamethasone intravitreal implant 0.7 mg) and ILUVIEN ® (fluocinolone acetonide intravitreal implant 190 µg) -the two sustainedrelease intravitreal corticos teroid formulations currently approved for the treatment of diabetic macular edema. The table accurately summarizes the efficacy and safety data from the published MEAD 2 and FAME 3 studies -all doses investigated in these Phase III trials are presented and clearly annotated in the table. In the case of the FAME study, this includes both the lowdose (0.2 µg/day) and highdose (0.5 µg/day) formulations of fluocinolone acetonide intravitreal implant 190 µg. The data, therefore, are relevant to the product currently marketed in Europe and the United States, ILUVIEN, which releases 0.2 µg of fluocinolone acetonide per day.
The content of the amended table presented by Dr Hall, based as it is on the European Summary of Product Charac teristics for ILUVIEN, goes well beyond the scope and intent of our original table. Other than referring to the date of US Food and Drug Administration approval, our article avoids all mention of product licensing and labeling in the various regional markets. We feel that these marketing details would be out of place in a review of the scientific literature.
